Envudeucitinib vs TQH3906

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: TYK2 · full Psoriasis pipeline

Envudeucitinib

Developed by Alumis and partners

Phase 3 in Psoriasissmall molecule
Reliable signal

NCT06586112 · Phase 3 · completed

Participants were randomized and blinded across drug, placebo, and active-comparator arms. A much larger share of patients on envudeucitinib achieved high levels of skin clearance than on placebo, with a highly significant difference.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2027 · NCT05739435 (registry estimate)

Reported efficacy

To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo (16 weeks): PASI-75 at week 16 (ONWARD 1): 76.5% envudeucitinib vs 18.7% placebo; PASI-90: 59.9% vs 4.8%; PASI-100: 29.4% vs 0.9% (P<.0001 for all) (met)

Result source: NCT06586112

TQH3906

Developed by Sino Biopharmaceutical

Phase 3 in PsoriasisSmall molecule (oral TYK2 inhibitor)
Partial signal

NCT06542614 · Phase 2 · completed

This Phase 2 trial randomly assigned 209 people with plaque psoriasis to TQH3906 or placebo, with participants, carers, investigators and outcome assessors unaware of assignment. The primary measure was the proportion reaching PASI 75, a 75% improvement in psoriasis severity, at week 12. The sponsor reports more than 90% reaching PASI 75 and more than 70% reaching PASI 90 at the recommended dose, but gives no placebo figure and no statistical comparison, so the size of the advantage over placebo is not established by what has been released.

Next expected readout: September 2027 · NCT07724366 (registry estimate)

Reported efficacy

Proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75 at week 12 (Up to week 12): At the recommended dose in the 209-patient study: PASI 75 above 90% and PASI 90 above 70% at 12 weeks (met)

Result source: NCT06542614

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEnvudeucitinibTQH3906
PASI 7556.4% vs 0%+56.4 vs placebo40mg QD · wk 12 · n 39NCT05600036
4 other results
  • 64.1% vs 0% 40mg BID · wk 12 · n 39 · Phase 2 · primary NCT05600036
  • 33.3% vs 0% 20mg QD · wk 12 · n 36 · Phase 2 · primary NCT05600036
  • 56.4% vs 0% 20mg BID · wk 12 · n 39 · Phase 2 · primary NCT05600036
  • 19.4% vs 0% 10mg QD · wk 12 · n 36 · Phase 2 · primary NCT05600036
—Trial running · NCT07724366
PASI 90—Not posted · NCT06588738—Trial running · NCT07724366
PASI 100—Not posted · NCT06588738—Trial running · NCT07724366
sPGA 0/153.8% vs 7.9%+45.9 vs placebo40mg QD · wk 12 · n 39NCT05600036
4 other results
  • 59% vs 7.9% 40mg BID · wk 12 · n 39 · Phase 2 · secondary NCT05600036
  • 38.9% vs 7.9% 20mg QD · wk 12 · n 36 · Phase 2 · secondary NCT05600036
  • 48.7% vs 7.9% 20mg BID · wk 12 · n 39 · Phase 2 · secondary NCT05600036
  • 16.7% vs 7.9% 10mg QD · wk 12 · n 36 · Phase 2 · secondary NCT05600036
—Trial running · NCT07724366
DLQI, change—Not posted · NCT06588738—Trial running · NCT07724366

PASI 75

Envudeucitinib
56.4% vs 0%+56.4 vs placebo40mg QD · wk 12 · n 39NCT05600036
4 other results
  • 64.1% vs 0% 40mg BID · wk 12 · n 39 · Phase 2 · primary NCT05600036
  • 33.3% vs 0% 20mg QD · wk 12 · n 36 · Phase 2 · primary NCT05600036
  • 56.4% vs 0% 20mg BID · wk 12 · n 39 · Phase 2 · primary NCT05600036
  • 19.4% vs 0% 10mg QD · wk 12 · n 36 · Phase 2 · primary NCT05600036
TQH3906
—Trial running · NCT07724366

PASI 90

Envudeucitinib
—Not posted · NCT06588738
TQH3906
—Trial running · NCT07724366

PASI 100

Envudeucitinib
—Not posted · NCT06588738
TQH3906
—Trial running · NCT07724366

sPGA 0/1

Envudeucitinib
53.8% vs 7.9%+45.9 vs placebo40mg QD · wk 12 · n 39NCT05600036
4 other results
  • 59% vs 7.9% 40mg BID · wk 12 · n 39 · Phase 2 · secondary NCT05600036
  • 38.9% vs 7.9% 20mg QD · wk 12 · n 36 · Phase 2 · secondary NCT05600036
  • 48.7% vs 7.9% 20mg BID · wk 12 · n 39 · Phase 2 · secondary NCT05600036
  • 16.7% vs 7.9% 10mg QD · wk 12 · n 36 · Phase 2 · secondary NCT05600036
TQH3906
—Trial running · NCT07724366

DLQI, change

Envudeucitinib
—Not posted · NCT06588738
TQH3906
—Trial running · NCT07724366
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

TQH3906
At the recommended dose in the 209-patient study: PASI 75 above 90% and PASI 90 above 70% at 12 weeks NCT06542614 · Phase 2 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Envudeucitinib: 4 of 4 rows · TQH3906: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEnvudeucitinib
Dropout rate
10.3%40mg BIDa
NCT05600036 · Phase 2 · registry result, not featured evidence
show 4 more results
15.4%40mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
7.5%20mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence
16.7%20mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
0%10mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
2.6%40mg BIDa
NCT05600036 · Phase 2 · registry result, not featured evidence
show 4 more results
2.6%40mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
0%20mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence
5.6%20mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
0%10mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
Serious AEs
0%40mg BIDa
NCT05600036 · Phase 2 · registry result, not featured evidence
show 4 more results
2.6%40mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
7.7%20mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence
0%20mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
2.8%10mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
40mg BIDa
headache 7.7% (placebo 5.3%)
nasopharyngitis 7.7% (placebo 7.9%)
upper respiratory tract infection 7.7% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence
show 4 more results
40mg QD
headache 10.3% (placebo 5.3%)
acne 5.1% (placebo 0%)
upper respiratory tract infection 5.1% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence
20mg BID
headache 7.7% (placebo 5.3%)
cough 5.1% (placebo 0%)
diarrhea 5.1% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence
20mg QD
headache 5.6% (placebo 5.3%)
upper respiratory tract infection 5.6% (placebo 0%)
acne 0% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence
10mg QD
diabetes mellitus 5.6% (placebo 0%)
nasopharyngitis 5.6% (placebo 7.9%)
upper respiratory tract infection 5.6% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Envudeucitinib

PASI 75 56.4% (n=39) vs 0% (n=38) placebo @ 12wk40mg QD
responder rate · % of participants
NCT05600036 · Phase 2 · registry result, not featured evidence
show 4 more results
64.1% (n=39) vs 0% (n=38) placebo @ 12wk40mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence
33.3% (n=36) vs 0% (n=38) placebo @ 12wk20mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
56.4% (n=39) vs 0% (n=38) placebo @ 12wk20mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence
19.4% (n=36) vs 0% (n=38) placebo @ 12wk10mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
sPGA 0/1 53.8% (n=39) vs 7.9% (n=38) placebo @ 12wk40mg QD
responder rate · % of participants
NCT05600036 · Phase 2 · registry result, not featured evidence · converted to % from 21 Participants as posted
show 4 more results
59% (n=39) vs 7.9% (n=38) placebo @ 12wk*40mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence · converted to % from 23 Participants as posted
38.9% (n=36) vs 7.9% (n=38) placebo @ 12wk*20mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence · converted to % from 14 Participants as posted
48.7% (n=39) vs 7.9% (n=38) placebo @ 12wk*20mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence · converted to % from 19 Participants as posted
16.7% (n=36) vs 7.9% (n=38) placebo @ 12wk*10mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence · converted to % from 6 Participants as posted

Systemic Lupus Erythematosus

Shared mechanism: TYK2 · full Systemic Lupus Erythematosus pipeline

Envudeucitinib

Developed by Alumis and partners

Phase 2 in Systemic Lupus Erythematosussmall molecule
Partial signal

NCT05966480 · Phase 2 · active, not recruiting

The trial was well designed -- randomized, triple-blinded, placebo-controlled, and adequately sized (n=408) with a recognized disease-activity measure (BICLA) as its primary endpoint -- but the overall primary comparison did not reach statistical significance. A positive signal in one prespecified subgroup does not change the fact that the main, prespecified population analysis missed, so this remains solid but inconclusive evidence rather than strong evidence of a benefit.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

To compare the effect on disease activity measured by the proportion of patients achieving British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) response at Week 48 between doses of ESK-001 and placebo: LUMUS trial (NCT05966480), primary endpoint BICLA response: envudeucitinib did not meet its primary endpoint in the overall trial population, but a prespecified IFNGS-high subgroup showed robust clinical responses on the same primary endpoint (BICLA). (missed)

Result source: NCT05966480

TQH3906

Developed by Sino Biopharmaceutical

Phase 2 in Systemic Lupus ErythematosusSmall molecule (oral TYK2 inhibitor)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: November 2027 · NCT07509892 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Systemic Lupus Erythematosus

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEnvudeucitinibTQH3906
SRI-4—Not reported—Not reported
BICLA—Not reported—Not reported
CLASI-50—Not reported—Not reported
Steroid sparing—Not reported—Not reported

SRI-4

Envudeucitinib
—Not reported
TQH3906
—Not reported

BICLA

Envudeucitinib
—Not reported
TQH3906
—Not reported

CLASI-50

Envudeucitinib
—Not reported
TQH3906
—Not reported

Steroid sparing

Envudeucitinib
—Not reported
TQH3906
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

TQH3906: no structured comparison results are available for Systemic Lupus Erythematosus.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Envudeucitinib
LUMUS trial (NCT05966480), primary endpoint BICLA response: envudeucitinib did not meet its primary endpoint in the overall trial population, but a prespecified IFNGS-high subgroup showed robust clinical responses on the same primary endpoint (BICLA). NCT05966480 · Phase 2 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Envudeucitinib's landscape · TQH3906's landscape